EVPL

EVPL (envoplakin) is a plakin-family protein and a membrane-associated precursor of the epidermal cornified envelope, proposed on the basis of homology to desmoplakin, BPAG1, and plectin to link desmosomes and keratin filaments to the cornified envelope (PMID:8938451). Its expression in epithelial tissues is directly driven by the transcription factor p63, which binds a p63-specific response element (RRRCGTGYYY) in the EVPL promoter that is distinct from the canonical p53 element; EVPL protein is abundant in skin and pharyngeal epithelium of wild-type mice but absent in p63-null mice (PMID:15988020). This p63-driven transcription is potentiated by BRD4, which physically interacts with p63 and co-occupies the EVPL locus to coordinate EVPL expression during keratinocyte differentiation (PMID:39605045). Beyond its structural role, EVPL acts as a tumor suppressor that restrains the RAS/ERK signaling axis: EVPL overexpression suppresses melanoma cell proliferation, migration, and invasion, promotes apoptosis, and dampens chemokine-driven macrophage recruitment and M2 polarization, with epistasis experiments placing EVPL upstream of ERK (PMID:38504693). In breast cancer cells EVPL is repressed by AGTPBP1, and restoring EVPL attenuates AGTPBP1-induced ERK activation and malignancy, defining an AGTPBP1/EVPL/ERK axis (PMID:41905574). Although EVPL maps within the tylosis esophageal cancer locus on 17q25, mutation and haplotype analyses excluded it as the causative TOC gene and found only rare somatic mutation in sporadic esophageal carcinoma (PMID:10409435, PMID:15756445).

1. 1996 Medium

   Established the molecular identity and candidate function of EVPL by placing it in the plakin family and mapping its locus, framing it as a structural connector of desmosomes, keratin filaments, and the cornified envelope.

   Evidence Somatic cell hybrid analysis and in situ hybridisation with cosmid/YAC isolation, plus homology to desmoplakin/BPAG1/plectin

   PMID:8938451

   Open questions at the time

   • Structural linker role inferred from homology and expression, not directly tested
   • No direct demonstration of binding to desmosomal or keratin components
2. 1999 Medium

   Tested whether EVPL is the causative gene at the tylosis esophageal cancer (TOC) locus and excluded it, redirecting the search for the TOC gene.

   Evidence Mutation and haplotype analysis with radiation hybrid and physical mapping across three TOC families

   PMID:10409435

   Open questions at the time

   • Negative result does not address whether EVPL contributes to esophageal pathology by other mechanisms
   • Limited to three families
3. 2005 High

   Resolved how EVPL is transcriptionally controlled, showing it is a direct p63 target via a p63-discriminating promoter element, linking EVPL to epithelial differentiation programs.

   Evidence Microarray, mutagenized-promoter luciferase assays, EMSA, and p63 knockout mouse immunostaining

   PMID:15988020

   Open questions at the time

   • Does not establish EVPL's downstream functional consequences
   • Cofactors of p63 at the EVPL promoter not defined in this study
4. 2005 Medium

   Assessed whether EVPL is somatically targeted in sporadic esophageal squamous cell carcinoma and found mutation is rare despite frequent LOH, arguing against EVPL as the primary driver at the locus.

   Evidence RT-PCR SSCP and direct sequencing of EVPL in OSC cell lines and tumors

   PMID:15756445

   Open questions at the time

   • Single missense variant of unknown functional impact
   • Does not rule out epigenetic or expression-level inactivation
5. 2016 Medium

   Mapped the autoantigenic regions of EVPL in paraneoplastic pemphigus, localizing dominant epitopes to defined N-terminal and linker subdomains.

   Evidence ELISA of patient/control sera against 12 overlapping recombinant EVPL fragments

   PMID:27427435

   Open questions at the time

   • Does not address whether autoantibodies are pathogenic
   • Epitope mapping does not bear on normal EVPL function
6. 2021 Low

   Linked EVPL loss to therapy resistance, showing EVPL knockdown increases radioresistance in esophageal cancer cells with inferred suppression of inflammatory signaling.

   Evidence RNAi knockdown in KYSE-150 with clonogenic survival assay and RNA-seq

   PMID:33633453

   Open questions at the time

   • NF-κB/TNF pathway involvement inferred from transcriptome, not directly validated
   • Single cell line, single lab
7. 2024 Medium

   Identified BRD4 as a transcriptional coactivator partnering with p63 to drive EVPL, refining the regulatory logic of EVPL expression during keratinocyte differentiation.

   Evidence Co-IP, ChIP, RT-qPCR, transcriptomics, and JQ1/knockdown perturbation

   PMID:39605045

   Open questions at the time

   • EVPL is one of several co-regulated targets; EVPL-specific dependence on BRD4 not isolated
   • Direct vs indirect BRD4 effect at EVPL not fully separated
8. 2024 Medium

   Defined a functional tumor-suppressor role for EVPL upstream of ERK, showing EVPL restrains melanoma proliferation, invasion, and macrophage recruitment through RAS/ERK signaling.

   Evidence Gain/loss-of-function in melanoma cells with functional assays, co-culture, and ERK-inhibitor epistasis (SCH772984)

   PMID:38504693

   Open questions at the time

   • Molecular mechanism by which EVPL regulates RAS/ERK is undefined
   • Single lab, in vitro context
9. 2026 Medium

   Placed EVPL within a defined regulatory axis in breast cancer, showing AGTPBP1 represses EVPL to activate ERK and that restoring EVPL reverses malignancy.

   Evidence RNA-seq, gain/loss-of-function, and rescue experiments with pERK1/2 readout in two cell lines

   PMID:41905574

   Open questions at the time

   • Mechanism of AGTPBP1-mediated EVPL repression not established
   • Direct biochemical link between EVPL and ERK pathway components missing

• The molecular mechanism by which EVPL, a structural cornified-envelope protein, suppresses RAS/ERK signaling remains unresolved.
• No identified physical link between EVPL and RAS/ERK pathway components
• Whether the tumor-suppressive activity depends on EVPL's structural/desmosomal role is unknown
• No in vivo validation of the tumor-suppressor function